250 µCi quantities of SCH 23390, [N-Methyl-³H]-, are available for your research. SCH-23390 acts as an antagonist at the dopamine D₁ receptor. These receptors belong a family of GPCRs and are potential drug targets for Parkinson's disease, schizophrenia, and depression.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET930:

1. Finnema, S.J., Bang-Andersen, B., Jørgensen, M., Christoffersen, C.T., Gulyás, B., Wikström, H.V., Farde, L. and Halldin, C. (2013), The dopamine D1 receptor agonist (S)-[11C]N-methyl-NNC 01-0259 is not sensitive to changes in dopamine concentration—a positron emission tomography examination in the monkey brain. Synapse, 67: 586–595.
2. Wong, J., Clifford, J., Massalas, J., Finkelstein, D., Horne, M., Waddington, J., Drago, J. (2003) Neurochemical changes in dopamine D1, D3 and D1/D3 receptor knockout mice, European Journal of Pharmacology, 472 (1–2): 39-47.